Real-World Liraglutide Use for Weight Management in Europe

Obesity is a complex, chronic disease affecting millions globally, significantly increasing the risk of conditions like type 2 diabetes, cardiovascular disease, and certain cancers. Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is an approved medication for weight management. While clinical trials demonstrate its efficacy, there's a critical need to understand how liraglutide performs and is utilized in routine clinical practice across diverse European settings.

The retrospective analysis of 316 patient records revealed crucial insights into real-world liraglutide use for weight management. Patients typically presented with an average baseline BMI of 38.5 kg/m² and were predominantly female (68%), reflecting common demographics for weight management interventions. The majority of patients (75%) initiated treatment at 1.2 mg and successfully titrated to the full 3.0 mg dose within an average of 8-12 weeks, indicating good tolerability during dose escalation. Over a median follow-up period of 12 months, patients observed an average weight reduction of 7.2% from baseline, with 43% of patients achieving at least 5% total body weight loss, a clinically meaningful threshold. Treatment adherence was notable, with 65% of patients continuing liraglutide for at least 6 months, and 40% remaining on treatment for 12 months. Common reasons for discontinuation included gastrointestinal side effects (18%) and insufficient weight loss (12%), though these were generally mild and manageable, aligning with known safety profiles.